Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report)'s stock had its "buy" rating restated by investment analysts at Needham & Company LLC in a research report issued on Monday, Benzinga reports. They presently have a $56.00 price target on the stock. Needham & Company LLC's target price points to a potential upside of 474.54% from the stock's previous close.
Several other research firms have also recently commented on FTH. Lifesci Capital upgraded shares of Sensei Biotherapeutics to a "strong-buy" rating in a report on Thursday, October 15th. BTIG Research reiterated a "buy" rating and issued a $55.00 price objective on shares of Sensei Biotherapeutics in a research note on Tuesday, October 27th. William Blair assumed coverage on shares of Sensei Biotherapeutics in a research report on Friday, October 16th. They issued an "outperform" rating for the company. JonesTrading began coverage on shares of Sensei Biotherapeutics in a research note on Tuesday, August 4th. They set a "buy" rating and a $55.00 target price for the company. Finally, Oppenheimer began coverage on shares of Sensei Biotherapeutics in a research note on Tuesday, July 28th. They set an "outperform" rating and a $60.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $56.58.
Get Our Latest Stock Analysis on Sensei Biotherapeutics
Sensei Biotherapeutics Trading Down 2.8%
Sensei Biotherapeutics stock traded down $0.28 during mid-day trading on Monday, hitting $9.75. The company's stock had a trading volume of 133,878 shares, compared to its average volume of 286,625. The stock's 50 day moving average is $25.07. The firm has a market cap of $251.90 million, a P/E ratio of -0.07 and a beta of -0.15. Sensei Biotherapeutics has a 52-week low of $7.45 and a 52-week high of $42.14.
Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.13). As a group, equities analysts forecast that Sensei Biotherapeutics will post -14.01 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Sensei Biotherapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in FTH. Jump Financial LLC acquired a new stake in shares of Sensei Biotherapeutics during the 3rd quarter valued at about $694,000. AWM Investment Company Inc. grew its stake in shares of Sensei Biotherapeutics by 4.5% in the 3rd quarter. AWM Investment Company Inc. now owns 116,344 shares of the company's stock valued at $3,460,000 after buying an additional 5,001 shares in the last quarter. State Street Corp acquired a new position in Sensei Biotherapeutics in the third quarter worth approximately $9,262,000. Candriam S.C.A. acquired a new position in Sensei Biotherapeutics in the third quarter worth approximately $9,542,000. Finally, State of Wyoming bought a new position in Sensei Biotherapeutics during the third quarter valued at approximately $25,000. 10.50% of the stock is owned by hedge funds and other institutional investors.
About Sensei Biotherapeutics
(
Get Free Report)
Sensei Biotherapeutics is a biotechnology company focused on developing immunotherapies for cancer. Its research centers on treatments intended to address immune suppression in the tumor microenvironment and help the body's immune system recognize and attack cancer cells. The company's publicly disclosed research programs have included SNS-101, an antibody designed to target VISTA, an immune checkpoint protein, and SNS-301, an investigational cancer immunotherapy. These programs were in development rather than marketed products.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sensei Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sensei Biotherapeutics wasn't on the list.
While Sensei Biotherapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.